Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Leiomyoma 6Myofibroma 1Metrorrhagia 1Menorrhagia 1

Interventions

Misoprostol 6Uterine Myomectomy 4relugolix 3Tranexamic Acid 3Saline Solution 3Hysterectomy 3dienogest 2carbetocin 2Uterine Artery Embolization 2Tourniquets 2Tablets 2Lidocaine 2Leuprolide 2Hysteroscopy 2Ascorbic Acid 2ulipristal 1telapristone acetate 1remimazolam 1ramosetron 1pirfenidone 1estradiol, norethindrone drug combination 1Vasopressins 1Triptorelin Pamoate 1Tranylcypromine 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sodium Chloride 1Sevoflurane 1Respiration, Artificial 1Remifentanil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myofibroma × ulipristal × Clear all
NCT00044876 2019-12-17

Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
56 enrolled

Leiomyoma, Myofibroma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡